Pregnancy Related
Conditions
Keywords
Autophagy, Apoptosis
Brief summary
The object of this study is to assess the intra- and inter-individual variability of apoptosis and autophagy activities in women during pregnancy: 1 / in women with a normal pregnancy and 2 / in pregnant women particularly at risk of complications. The study investigators hypothesize that there would be an intra-trophoblastic dialogue between the mechanisms of autophagy and apoptosis, the promotion of one partially inhibiting the other. The increase in trophoblastic autophagy during pregnancy could thus constitute an anti-apoptosis defense phenomenon, the exhaustion of which would lead to cellular apoptosis and to pathogenic consequences when it devastates the syncytiotrophoblast.
Interventions
OTHERBlood test
Blood samples taken to test levels of autophagy and apoptosis
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients followed at the CHU Nimes prior to 33 weeks gestation who give birth at the hospital * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan
Exclusion criteria
* The subject is participating in a category 1 interventional study associated with a medication, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Multiple pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Potential autophagy induction activity in all groups | Day 0 | Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Potential apoptosis induction activity in all groups | Day 0 | % cells positive for Annexin V |
| Inter- and intra-individual apoptosis/autophagy ratio in all groups | Day 0 | — |
| Autophagy kinetics between groups | Day 0 | measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio |
| Apoptosis kinetics between groups | Day 0 | measured by % cells positive for Annexin V |
| Placental Growth Factor in each group | Day 0 | pg/ml measured by ELISA |
| Soluble fms-like tyrosine kinase-1 | Day 0 | pg/ml measured by ELISA |
| Constitutive thrombophilia | Day 0 | presence/absence of the prothrombin gene or factor V Leiden mutation, protein S, C or antithrombin deficiency |
| Acquired thrombophilia | Day 0 | Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid). |
| Type of autophagy inhibition per patient in all groups | Day 0 | Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio |
| Renal function | Day 0 | creatinemia, proteinuria / creatinuria ratio |
| Fibrin levels | Day 0 | D dimers and fibrin monomers |
| Inflammation | Day 0 | C-reactive protein level |
| Activated partial thromboplastin time | Day 0 | seconds |
| Prothrombin time | Day 0 | seconds |
| Fibrinogen level | Day 0 | g/L |
| Thrombin generation time | Month 1 | seconds |
| fetal haemoglobin | Month 1 | g/L |
| Whole blood count | Day 0 | — |
Countries
France
Outcome results
None listed